The outlook of companies tied to Viagra's past presents a complex investment picture . While the initial boom generated substantial gains, generic copies have significantly diminished revenue. Investing in connected pharmaceutical firms now requires a careful assessment of patent safeguards, evolving medical changes, and the prospect for breakthrou